Company intelligence / Profile preview

Selkis Therapeutics

New York City, New York, United States

Ownership: Private
Development stage: Other

Overview

Phase 3 REGAL trial of galinpepimut-S (GPS) in AML received positive IDMC recommendation to continue without modification, with final analysis anticipated by year-end 2025; Phase 2 results of SLS009 in r/r AML met all primary endpoints with 44% ORR at optimal dose

Therapeutic areas: OncologyHematology
Modalities: Cancer immunotherapeutic agentSmall molecule
Industry: Biotech

Partnerships

Memorial Sloan Kettering Cancer Center (MSKCC)3D Medicines Inc.GenFleet Therapeutics (Shanghai) Inc.Merck

Beyond the preview

Go deeper on Selkis Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Selkis Therapeutics.

Explore the full profile